Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK.pptx (254.64 kB)
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK (2012)
poster
posted on 2020-02-28, 11:41 authored by Yang MengYang Meng, Hazel SquiresHazel Squires, John Stevens, Emma SimpsonEmma Simpson, Steve Thomas, Jonathan Michaels, Gerard Stansby, Mark O'DonnellThe study aims to assess the cost-effectiveness of the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conservative management.
History
Ethics
- The project has ethical approval and have included the number in the description field
Policy
- The data complies with the institution and funders' policies on access and sharing
Sharing and access restrictions
- The data can be shared openly
Data description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files
